LAVA Therapeutics NV (LAVA Therapeutics NV) Cash-to-Debt

: 15.14 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. LAVA Therapeutics NV's cash to debt ratio for the quarter that ended in Dec. 2023 was 15.14.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, LAVA Therapeutics NV could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for LAVA Therapeutics NV's Cash-to-Debt or its related term are showing as below:

LVTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 3.88 Med: 15.14 Max: 27.38
Current: 15.14

During the past 5 years, LAVA Therapeutics NV's highest Cash to Debt Ratio was 27.38. The lowest was 3.88. And the median was 15.14.

LVTX's Cash-to-Debt is ranked better than
61.66% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs LVTX: 15.14

LAVA Therapeutics NV Cash-to-Debt Historical Data

The historical data trend for LAVA Therapeutics NV's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

LAVA Therapeutics NV Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

4.16

3.88

27.38

24.38

15.14

LAVA Therapeutics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt													24.38	17.97	16.17	16.89	15.14

Competitive Comparison

For the Biotechnology subindustry, LAVA Therapeutics NV's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LAVA Therapeutics NV Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, LAVA Therapeutics NV's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where LAVA Therapeutics NV's Cash-to-Debt falls into.

LAVA Therapeutics NV Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

LAVA Therapeutics NV's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	95.571	/	(5.722	+	0.591)
	=	15.14

LAVA Therapeutics NV's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	95.571	/	(5.722	+	0.591)
	=	15.14

LAVA Therapeutics NV (NAS:LVTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

LAVA Therapeutics NV Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of LAVA Therapeutics NV's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

LAVA Therapeutics NV (LAVA Therapeutics NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LAVA Therapeutics NV (NAS:LVTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

4PKB:Germany

Address

Yalelaan 62, Utrecht, UT, NLD, 3584 CM

Website

https://www.lavatherapeutics.com

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.